A new class of antibiotics, gepotidacin, has shown success in treating gonorrhea in late-stage trials. The antibiotic, made by pharmaceutical company GSK under the name Blujepa, has previously won FDA approval for uncomplicated UTIs in women and girls aged 12 and above. With rising cases of antibiotic-resistant gonorrhea in the US, gepotidacin, if approved, would be the first new drug for the infection since the 1990s.
Immune Cell Type Linked to Oral Tolerance and Childhood Food Allergies
A study by Memorial Sloan Kettering Cancer Center researchers demonstrated that a recently discovered type of cell, called Thetis cells, play an important role in
